BioAffinity Technologies Valuation
| BIAFW Stock | USD 0.27 0.00 0.00% |
BioAffinity Technologies seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of BioAffinity Technologies from analyzing the firm fundamentals such as Operating Margin of (0.84) %, number of shares shorted of 1.1 K, and Return On Equity of -1.67 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioAffinity Technologies' price fluctuation is out of control at this time. Calculation of the real value of BioAffinity Technologies is based on 3 months time horizon. Increasing BioAffinity Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioAffinity stock is determined by what a typical buyer is willing to pay for full or partial control of bioAffinity Technologies Warrant. Since BioAffinity Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioAffinity Stock. However, BioAffinity Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.27 | Real 0.26 | Hype 0.31 | Naive 0.25 |
The intrinsic value of BioAffinity Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioAffinity Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of bioAffinity Technologies Warrant helps investors to forecast how BioAffinity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioAffinity Technologies more accurately as focusing exclusively on BioAffinity Technologies' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BioAffinity Technologies' intrinsic value based on its ongoing forecasts of BioAffinity Technologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BioAffinity Technologies' closest peers.
BioAffinity Technologies Cash |
|
BioAffinity Valuation Trend
Analysing the historical paterns of BioAffinity Technologies' enterprise value and its market capitalization is a good way to estimate and gauge the value of bioAffinity Technologies Warrant over time and is usually enough for investors to make rational market timing decisions.
BioAffinity Technologies Total Value Analysis
bioAffinity Technologies Warrant is currently forecasted to have takeover price of 0 with market capitalization of 0, debt of 1.58 M, and cash on hands of 214.4 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BioAffinity Technologies fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 1.58 M | 214.4 K |
BioAffinity Technologies Investor Information
The company had not issued any dividends in recent years. Based on the key indicators related to BioAffinity Technologies' liquidity, profitability, solvency, and operating efficiency, bioAffinity Technologies Warrant is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.BioAffinity Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioAffinity Technologies has an asset utilization ratio of 30.8 percent. This indicates that the Company is making $0.31 for each dollar of assets. An increasing asset utilization means that bioAffinity Technologies Warrant is more efficient with each dollar of assets it utilizes for everyday operations.BioAffinity Technologies Profitability Analysis
The company reported the revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 3.28 M.About BioAffinity Technologies Valuation
Our relative valuation model uses a comparative analysis of BioAffinity Technologies. We calculate exposure to BioAffinity Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioAffinity Technologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 910.4 K | 955.9 K | |
| Pretax Profit Margin | (2.81) | (2.95) | |
| Operating Profit Margin | (2.83) | (2.98) | |
| Net Loss | (2.82) | (2.96) | |
| Gross Profit Margin | 0.36 | 0.67 |
BioAffinity Technologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as BioAffinity Technologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 8.7 M | |
| Shares Float | 10.7 M |
BioAffinity Technologies Current Valuation Indicators
Valuation refers to the process of determining the present value of bioAffinity Technologies Warrant and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioAffinity we look at many different elements of the entity such as BioAffinity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioAffinity Technologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioAffinity Technologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioAffinity Technologies' worth.Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.